Drug acquisition costs are of increasing importance to budget-constrained healthcare systems.

Whilst human basal insulins for the management of type 2 diabetes mellitus are of lower acquisition cost compared to long-acting insulin analogues, it is important to consider value beyond price and to take into account the wider costs associated with insulin use over the full cycle of care and across the entire healthcare system.

The health impact of glycaemic control, hypoglycaemia, weight gain and ease of treatment represents a significant value consideration, beyond price, for the use of basal insulin analogues to manage type 2 diabetes mellitus from the perspective of all stakeholders within the healthcare system, including payers, healthcare professionals, patients and society.